15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer

Cancer Biology and Therapy

Volumn 10, Issue 8, 2010, Pages 780-787

  Liu, Zhenxiong ^a,b   Wang, Xin ^a   Lu, Yuanyuan ^a   Du, Rui ^a   Luo, Guanhong ^a   Wang, Jun ^a   Zhai, Huihong ^a   Zhang, Faming ^a   Wen, Qinsheng ^b   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

15 PGDH; Carcinogenesis; Catabolic enzyme; COX 2; Gastric cancer; Prostaglandin; Tumor suppressor

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; COMPLEMENTARY DNA; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MKN45; CELL STRAIN SGC7901; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; STOMACH CANCER;

ANIMALS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RNA INTERFERENCE; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS;

EID: 78049296961     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.8.12896     Document Type: Article

References (49)

1. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30:377-86.
2. Oshima H, Itadani H, Kotani H, Taketo MM, Oshima M. Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res 2009; 69:2729-33.
3. Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM, Oshima M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 2006; 131:1086-95. (Pubitemid 44498691)
4. Guo X, Oshima H, Kitmura T, Taketo MM, Oshima M. Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem 2008; 283:19864-71.
5. Leone V, di Palma A, Ricchi P, Acquaviva F, Giannouli M, Di Prisco AM, et al. PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through RAS-PI3K association and cAMP-dependent Kinase A activation. Am J Physiol Gastrointest Liver Physiol 2007; 293:673-81.
6. Oshima H, Oguma K, Du YC, Oshima M. Prostaglandin E, Wnt and BMP in gastric tumor mouse models. Cancer Sci 2009; 100:1779-85.
7. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, et al. 15-Hydroxyprostaglandin dehydrogenase is downregulated in colorectal cancer. J Biol Chem 2005; 280:3217-23.
8. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55:115-22.
9. Yang L, Amann JM, Kikuchi T, Porta R, Guix M, Gonzalez A, et al. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res 2007; 67:5587-93.
10. Magari H, Shimizu Y, Inada K, Enomoto S, Tomeki T, Yanaoka K, et al. Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. Biochem Biophys Res Commun 2005; 334:606-12.
11. Thiel A, Heinonen M, Rintahaka J, Hallikainen T, Hemmes A, Dixon DA, et al. Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. J Biol Chem 2006; 281:4564-9.
12. Forones NM, Kawamura KY, Segreto HR, Artigiani Neto R, Focchi GR, Oshima CT. Expression of COX-2 in stomach carcinogenesis. J Gastrointest Cancer 2008; 39:4-10.
13. Nam KT, Hahm KB, Oh SY, Yeo M, Han SU, Ahn B, et al. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clin Cancer Res 2004; 10:8105-13.
14. Yanaoka K, Oka M, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, et al. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion.
15. Rocha FT, Lourenço LG, Jucá MJ, Costa V, Leal AT. Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy. Acta Cir Bras 2009; 24:189-94.
16. Sahin M, Sahin E, Gümüslü S. Cyclooxygenase-2 in cancer and angiogenesis. Angiology 2009; 60:242-53.
17. Salzberg DJ, Weir MR. COX-2 inhibitors and cardiovascular risk. Subcell Biochem 2007; 42:159-74.
18. Brophy JM. Cardiovascular effects of cyclooxygenase-2 inhibitors. Curr Opin Gastroenterol 2007; 23:617-24.
19. Mason RP, Walter MF, McNulty HP, Lockwood SF, Byun J, Day CA, et al. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: A mechanism of cardiotoxicity. J Cardiovasc Pharmacol 2006; 47:7-14.
20. Farooq M, Haq I, Qureshi AS. Cardiovascular risks of COX inhibition: Current perspectives. Expert Opin Pharmacother 2008; 9:1311-9. (Pubitemid 351877515)
21. Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost 2006; 96:393-400.
22. +-dependent 15-hydroxyprostaglandin dehydrogenase. A key enzyme for the catabolism of the prostaglandins. J Lipid Mediat 1995; 12:313-9.
23. +-linked 15-hydroxyprostaglandin dehydrogenase: Structure and biological functions. Curr Pharm Des 2006; 12:955-62.
24. Chi X, Freeman BM, Tong M, Zhao Y, Tai HH. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is upregulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys 2009; 487:139-45.
25. Huang G, Eisenberg R, Yan M, Monti S, Lawrence E, Fu P, et al. 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res 2008; 68:5040-8.
26. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005; 65:7917-25.
27. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, et al 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci USA 2009; 206:9409-13.
28. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res2006; 66:7818-23.
29. Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A. Prostaglandin dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat 2006; 81:14-30.
30. Thill M, Fischer D, Becker S, Cordes T, Dittmer C, Diedrich K, et al. Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines. Anticancer Res 2009; 29:3619-25.
31. Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D. Calcitriol and genistein actions to inhibit the prostaglandin pathway: Potential combination therapy to treat prostate cancer. J Nutr 2007; 137:205-10.
32. Thiel A, Ganesan A, Mrena J, Junnila S, Nykänen A, Hemmes A, et al. 15-hydroxyprostaglandin dehydrogenase is downregulated in gastric cancer. Clin Cancer Res 2009; 15:4572-80.
33. Jang TJ, Ji YS, Jung KH. Decreased expression of 15-hydroxyprostaglandin dehydrogenase in gastric carcinomas. Yonsei Med J 2008; 49:917-22.
34. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGFbeta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 2004; 101:17468-73.
35. Liu Z, Wang X, Lu Y, Han S, Zhang F, Zhai H, et al. Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis 2008; 29:1219-27.
36. Ikeguchi M, Liu J, Kaibara N. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis 2002; 7:23-9. (Pubitemid 34145388)
37. Qing C, Jiang C, Zhang JS, Ding J. Induction of apoptosis in human leukemia K-562 and gastric carcinoma SGC-7901 cells by salvicine, a novel anticancer compound. Anticancer Drugs 2001; 12:51-6.
38. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9:138-41.
39. Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: The role of homeostasis. Carcinogenesis 2000; 21:857-64.
40. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004; 53:195-200.
41. Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003; 111:915-25.
42. Leung WK, Wu KC, Wong CY, Cheng AS, Ching AK, Chan AW, et al. Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. Carcinogenesis 2008; 29:1648-54.
43. Yeh TS, Wu CW, Hsu KW, Liao WJ, Yang MC, Li AF, et al. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase- 2. Cancer Res 2009; 69:5039-48.
44. Pham H, Eibl G, Vincenti R, Chong B, Tai HH, Slice LW. 15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice. Mol Carcinog 2008; 47:466-77.
45. +-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005; 26:65-72.
46. Tai HH, Tong M, Ding Y. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat 2007; 83:203-8. (Pubitemid 46661259)
47. Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T, Dey SK, et al. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res 2008; 68:9331-7.
48. +-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes. Am J Physiol Gastrointest Liver Physiol 2009; 297:559-66.
49. Pan Y, Bi F, Liu N, Xue Y, Yao X, Zheng Y, et al. Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun 2004; 315:686-91.